"The receipt of our Dealer's License is another key step in our international expansion plans as we are now positioned to expand our medical product offering not only to the German market but also provide a broad range of products to other European and key global markets," said Greg Engel, CEO of Organigram. "Additionally, we can now begin extensive research on new formulations to advance our product offerings in the future."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.